Cargando…

The Reevaluation of Thrombin Time Using a Clot Waveform Analysis

Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Hideo, Ichikawa, Yuhuko, Ezaki, Minoru, Matsumoto, Takeshi, Yamashita, Yoshiki, Shiraki, Katsuya, Shimaoka, Motomu, Shimpo, Hideto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585015/
https://www.ncbi.nlm.nih.gov/pubmed/34768360
http://dx.doi.org/10.3390/jcm10214840
_version_ 1784597588407746560
author Wada, Hideo
Ichikawa, Yuhuko
Ezaki, Minoru
Matsumoto, Takeshi
Yamashita, Yoshiki
Shiraki, Katsuya
Shimaoka, Motomu
Shimpo, Hideto
author_facet Wada, Hideo
Ichikawa, Yuhuko
Ezaki, Minoru
Matsumoto, Takeshi
Yamashita, Yoshiki
Shiraki, Katsuya
Shimaoka, Motomu
Shimpo, Hideto
author_sort Wada, Hideo
collection PubMed
description Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a low concentration of thrombin was evaluated using a CWA. We evaluated the CWA-TT of plasma deficient in various clotting factors, calibration plasma, platelet-poor plasma (PPP), and platelet-rich plasma (PRP) obtained from healthy volunteers, patients with thrombocytopenia, and patients with malignant disease. Results: Although the TT-CWA of calibration plasma was able to be evaluated with 0.01 IU/mL of thrombin, that of FVIII-deficient plasma could not be evaluated. The peak time of CWA-TT was significantly longer, and the peak height significantly lower, in various deficient plasma, especially in FVIII-deficient plasma compared to calibration plasma. The second peak of the first derivative (1st DP-2) was detected in PPP from healthy volunteers, and was shorter and higher in PRP than in PPP. The 1st DP-2 was not detected in PPP from patients with thrombocytopenia, and the 1st DP-2 in PRP was significantly lower in patients with thrombocytopenia and significantly higher in patients with malignant disease than in healthy volunteers. Conclusion: The CWA-TT became abnormal in plasma deficient in various clotting factors, and was significantly affected by platelets, suggesting that the CWA-TT may be a useful test for hemostatic abnormalities.
format Online
Article
Text
id pubmed-8585015
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85850152021-11-12 The Reevaluation of Thrombin Time Using a Clot Waveform Analysis Wada, Hideo Ichikawa, Yuhuko Ezaki, Minoru Matsumoto, Takeshi Yamashita, Yoshiki Shiraki, Katsuya Shimaoka, Motomu Shimpo, Hideto J Clin Med Article Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a low concentration of thrombin was evaluated using a CWA. We evaluated the CWA-TT of plasma deficient in various clotting factors, calibration plasma, platelet-poor plasma (PPP), and platelet-rich plasma (PRP) obtained from healthy volunteers, patients with thrombocytopenia, and patients with malignant disease. Results: Although the TT-CWA of calibration plasma was able to be evaluated with 0.01 IU/mL of thrombin, that of FVIII-deficient plasma could not be evaluated. The peak time of CWA-TT was significantly longer, and the peak height significantly lower, in various deficient plasma, especially in FVIII-deficient plasma compared to calibration plasma. The second peak of the first derivative (1st DP-2) was detected in PPP from healthy volunteers, and was shorter and higher in PRP than in PPP. The 1st DP-2 was not detected in PPP from patients with thrombocytopenia, and the 1st DP-2 in PRP was significantly lower in patients with thrombocytopenia and significantly higher in patients with malignant disease than in healthy volunteers. Conclusion: The CWA-TT became abnormal in plasma deficient in various clotting factors, and was significantly affected by platelets, suggesting that the CWA-TT may be a useful test for hemostatic abnormalities. MDPI 2021-10-21 /pmc/articles/PMC8585015/ /pubmed/34768360 http://dx.doi.org/10.3390/jcm10214840 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wada, Hideo
Ichikawa, Yuhuko
Ezaki, Minoru
Matsumoto, Takeshi
Yamashita, Yoshiki
Shiraki, Katsuya
Shimaoka, Motomu
Shimpo, Hideto
The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_full The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_fullStr The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_full_unstemmed The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_short The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_sort reevaluation of thrombin time using a clot waveform analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585015/
https://www.ncbi.nlm.nih.gov/pubmed/34768360
http://dx.doi.org/10.3390/jcm10214840
work_keys_str_mv AT wadahideo thereevaluationofthrombintimeusingaclotwaveformanalysis
AT ichikawayuhuko thereevaluationofthrombintimeusingaclotwaveformanalysis
AT ezakiminoru thereevaluationofthrombintimeusingaclotwaveformanalysis
AT matsumototakeshi thereevaluationofthrombintimeusingaclotwaveformanalysis
AT yamashitayoshiki thereevaluationofthrombintimeusingaclotwaveformanalysis
AT shirakikatsuya thereevaluationofthrombintimeusingaclotwaveformanalysis
AT shimaokamotomu thereevaluationofthrombintimeusingaclotwaveformanalysis
AT shimpohideto thereevaluationofthrombintimeusingaclotwaveformanalysis
AT wadahideo reevaluationofthrombintimeusingaclotwaveformanalysis
AT ichikawayuhuko reevaluationofthrombintimeusingaclotwaveformanalysis
AT ezakiminoru reevaluationofthrombintimeusingaclotwaveformanalysis
AT matsumototakeshi reevaluationofthrombintimeusingaclotwaveformanalysis
AT yamashitayoshiki reevaluationofthrombintimeusingaclotwaveformanalysis
AT shirakikatsuya reevaluationofthrombintimeusingaclotwaveformanalysis
AT shimaokamotomu reevaluationofthrombintimeusingaclotwaveformanalysis
AT shimpohideto reevaluationofthrombintimeusingaclotwaveformanalysis